Biocartis Group Past Earnings Performance

Past criteria checks 0/6

Biocartis Group's earnings have been declining at an average annual rate of -7.1%, while the Medical Equipment industry saw earnings declining at 9.5% annually. Revenues have been growing at an average rate of 16.2% per year.

Key information

-7.1%

Earnings growth rate

-2.2%

EPS growth rate

Medical Equipment Industry Growth-9.5%
Revenue growth rate16.2%
Return on equityn/a
Net Margin-111.6%
Last Earnings Update30 Jun 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Biocartis Group makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

LSE:0R72 Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2361-68370
31 Mar 2359-67370
31 Dec 2258-65370
30 Sep 2258-64360
30 Jun 2259-63350
31 Mar 2257-67340
31 Dec 2155-71320
30 Sep 2158-70320
30 Jun 2161-69320
31 Mar 2158-66310
31 Dec 2056-63300
30 Sep 2047-64310
30 Jun 2038-66310
31 Mar 2038-65320
31 Dec 1938-64320
30 Sep 1935-60300
30 Jun 1933-56280
31 Mar 1931-52250
31 Dec 1829-48230
30 Sep 1829-44220
30 Jun 1829-40210
31 Mar 1826-41200
31 Dec 1723-42180
30 Sep 1719-46170
30 Jun 1714-50160
31 Mar 1714-50160
31 Dec 1614-50160
30 Sep 1614-48160
30 Jun 1614-47170
31 Mar 1615-43160
31 Dec 1515-40150
30 Sep 1515-35140
30 Jun 1515-30130
31 Mar 1513-29120
31 Dec 1410-29100
31 Dec 1312-2780
31 Dec 126-3770

Quality Earnings: 0R72 is currently unprofitable.

Growing Profit Margin: 0R72 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0R72 is unprofitable, and losses have increased over the past 5 years at a rate of 7.1% per year.

Accelerating Growth: Unable to compare 0R72's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0R72 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-12.2%).


Return on Equity

High ROE: 0R72's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/12/23 17:40
End of Day Share Price 2023/09/25 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Biocartis Group NV is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Scott BardoBerenberg
Hugo SolvetBryan Garnier & Co
Guy SipsKBC Securities NV